Positions 76–95 of 95.
the STEP thing finally clicked for me and I want to write it down. Change my mind, genuinely — I have no stake in being right about this. On means, which this board…
The title is the argument: FLOW got published and nobody in here is talking about eGFR slope. Here is the rest of it. Intention-to-treat analyses everybody randomised…
Posting this as a discussion rather than a claim: TRIUMPH is doing more work than we give it credit for. Why comparing across trials almost never works, with the…
intent-to-treat vs per-protocol explains half the arguments on this site. Change my mind, genuinely — I have no stake in being right about this. On means, which this…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netunpopular opinion: most of what gets said here about hazard ratio is guesswork. Not a hot take, just something I have not seen said plainly here. A confidence interval…
Posting this as a discussion rather than a claim: SURPASS — 7 things I got wrong before I got it right. Compared myself to a trial mean for about six months before…
SURPASS — 17 things I got wrong before I got it right, which sounds obvious until you try to state the evidence for it. Discontinuation rates are a tolerability result.…
Question in the title, detail here: can we stop arguing about TRIUMPH until somebody posts a number. Intention-to-treat analyses everybody randomised regardless of what…
The title is the argument: TRIUMPH is doing more work than we give it credit for. Here is the rest of it. Went looking for the registered protocol to see whether the…
SELECT: MACE HR 0.80, and the absolute numbers people skip — a position I have arrived at slowly and would like tested. Compared myself to a trial mean for about six…
Something I keep coming back to: the STEP question that gets asked weekly, answered properly. Cardiovascular outcome trials are powered for events, not for weight, and…
hazard ratio is the most under-discussed thing on this board. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix…
Something I keep coming back to: three years of SURMOUNT threads, summarised so you do not have to read them. Cardiovascular outcome trials are powered for events, not…
reading SURMOUNT threads from 2024 and half of it aged badly, and I am aware this is a minority view on this board. Open-label extensions lose their randomisation.…
STEP is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. On means, which this board treats as targets…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsPosting this as a discussion rather than a claim: three years of SURMOUNT threads, summarised so you do not have to read them. Relative risk reduction without the…
the FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open. The discontinuation numbers…
The title is the whole question — help me understand SURMOUNT, I have read the wiki twice — but here is why I am asking. Discontinuation rates are a tolerability…
Thinking out loud about this: SURPASS — 10 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing…
FLOW (Perkovic et al., N Engl J Med , 2024) reported a hazard ratio of 0.76 for the composite kidney endpoint in people with type 2 diabetes and chronic kidney disease.…
Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference